KMDA.TA - Kamada Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
2,060.00
+35.00 (+1.73%)
At close: 5:24PM IDT
Stock chart is not supported by your current browser
Previous Close2,025.00
Open2,028.00
Bid2,059.00 x 346500
Ask2,060.00 x 57900
Day's Range2,010.00 - 2,060.00
52 Week Range1,481.00 - 2,060.00
Volume92,294
Avg. Volume54,103
Market Cap829.511M
Beta0.54
PE Ratio (TTM)6,732.03
EPS (TTM)0.31
Earnings DateAug 1, 2018 - Aug 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.00
  • GlobeNewswire10 days ago

    Kamada Receives Positive Scientific Advice from European Medicines Agency on a New Phase 3 Study Design for Inhaled AAT

    The Company requested scientific advice (protocol assistance) from the CHMP following the results of the previous Phase 2/3 (EU) and Phase 2 (US) studies conducted by the Company with respect to a proposed subsequent Phase 3 study design. The CHMP notified the Company that it concurs with the overall design of the proposed study, including its objectives, patient population, proposed endpoints and their clinical importance, and the safety monitoring plan.

  • Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?
    Zacks22 days ago

    Is Kamada (KMDA) Outperforming Other Medical Stocks This Year?

    Is (KMDA) Outperforming Other Medical Stocks This Year?

  • GlobeNewswire2 months ago

    Results of Kamada’s Phase 2 Trial of Alpha-1 Antitrypsin in Newly Diagnosed Type-1 Diabetes Patients to be Presented at the Upcoming American Diabetes Association’s 78th Scientific Sessions

    “We are excited to present the data from our Phase 2 trial of AAT in newly diagnosed T1D patients at such a prestigious medical conference,” said Amir London, Kamada’s Chief Executive Officer.  “Based on the results generated to date, and feedback received from the medical community, we believe that further studies in a larger population are warranted.

  • Associated Press2 months ago

    Kamada: 1Q Earnings Snapshot

    On a per-share basis, the Ness Ziona, Israel-based company said it had profit of 3 cents. The biopharmaceutical posted revenue of $17.4 million in the period. Kamada expects full-year revenue in the range ...

  • GlobeNewswire2 months ago

    Kamada Reports Financial Results for First Quarter of 2018

    Reaffirming Guidance of $116 to $120 Million in Total Revenues for 2018 U.S. Launch of KEDRAB ® Represents Significant Company Milestone REHOVOT, Israel, May 15, 2018-- Kamada Ltd., a plasma-derived protein ...

  • GlobeNewswire2 months ago

    Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15

    Kamada Ltd. (KMDA) (KMDA.TA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter ended March 31, 2018, prior to the open of the U.S. financial markets on Tuesday, May 15, 2018. Kamada management will host an investment community conference call on Tuesday, May 15 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the conference call by dialing 866-548-4713 (from within the U.S.), 1 80 924 3003 (from Israel), or 323-794-2093 (International) and entering the conference identification number: 2302061.

  • Business Wire2 months ago

    Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

    Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.

  • GlobeNewswire2 months ago

    Kedrion Biopharma and Kamada Announce KEDRAB® (Rabies Immune Globulin ) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

    Kedrion Biopharma and Kamada Ltd. (KMDA) (KMDA.TA), two leading human-derived protein therapeutics companies, announced today that KEDRAB® [Rabies Immune Globulin (Human)] has been launched in the U.S. and initial shipments are now reaching healthcare practitioners across the country. Deliveries have been timed to meet growing demand for this product as the height of the 2018 spring/summer rabies season approaches. KEDRAB, a human rabies immune globulin (HRIG), received U.S. Food and Drug Administration (FDA) approval for passive, transient post-exposure prophylaxis of rabies infection, when given immediately after contact with a rabid or possibly rabid animal and concurrent with the rabies vaccine. Prior to FDA approval of KEDRAB, U.S. healthcare professionals had only two HRIG therapy options from which to choose to prevent the onset of rabies in someone who may have been exposed to the deadly virus. KEDRAB, the newest entry into the $100 million plus U.S. rabies market, represents another safe, effective treatment choice for healthcare professionals seeking an alternative to currently available HRIGs.

  • MarketWatch3 months ago

    Kamada shares drop on FDA's continued concerns about therapy's safety, trial delay

    Kamada Ltd. shares dropped 4.4% in premarket trade Monday on news that the company has not been able to resolve the Food and Drug Administration's concerns about the safety of its therapy, which will delay a phase 3 clinical trial that Kamada had planned for the second half of the year. It's also possible the trial may not happen, Kamada suggested. The product, Inhaled Alpha-1 Antitrypsin, is intended to treat Alpha-1 Antitrypsin Deficiency, a genetic disorder that can lead to lung and liver disease.

  • GlobeNewswire3 months ago

    Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

    REHOVOT, Israel, April 23, 2018-- Kamada Ltd., a plasma-derived protein therapeutics company, today announced that the Company recently received feedback from the U.S. Food and Drug Administration regarding ...

  • Associated Press5 months ago

    Kamada posts 4Q profit

    On a per-share basis, the Ness Ziona, Israel-based company said it had net income of 16 cents. The biopharmaceutical posted revenue of $35.7 million in the period. For the year, the company reported net ...

  • Kamada Ltd. breached its 50 day moving average in a Bullish Manner : KMDA-IL : November 16, 2017
    Capital Cube8 months ago

    Kamada Ltd. breached its 50 day moving average in a Bullish Manner : KMDA-IL : November 16, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Kamada Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Associated Press8 months ago

    Kamada reports 3Q loss

    The Ness Ziona, Israel-based company said it had a loss of 1 cent per share. Earnings, adjusted for stock option expense, were less than 1 cent on a per-share basis. The biopharmaceutical posted revenue ...

  • Kamada Ltd. breached its 50 day moving average in a Bearish Manner : KMDA-IL : November 3, 2017
    Capital Cube9 months ago

    Kamada Ltd. breached its 50 day moving average in a Bearish Manner : KMDA-IL : November 3, 2017

    Categories: Europe Stock Alerts Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Kamada Ltd.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)